Factors Associated with Recovery of Renal Function in Patients with Multiple Myeloma Who Were Treated with Hemodialysis

被引:8
作者
Katagiri, Daisuke
Hagiwara, Shotaro [2 ]
Minami, Eri
Katsuma, Ai
Masumoto, Shoichi
Hoshino, Taro
Inoue, Tsuyoshi
Shibata, Maki
Tada, Manami
Nakamura, Taichi
Shimbo, Takuro [3 ]
Hinoshita, Fumihiko [1 ]
机构
[1] Natl Ctr Global Hlth & Med, Dept Nephrol, Res Inst, Shinjuku Ku, Tokyo, Japan
[2] Natl Ctr Global Hlth & Med, Res Inst, Div Hematol, Tokyo, Japan
[3] Natl Ctr Global Hlth & Med, Res Inst, Dept Clin Res & Informat, Tokyo, Japan
来源
NEPHRON CLINICAL PRACTICE | 2011年 / 117卷 / 01期
关键词
Multiple myeloma; Hemodialysis; Prognostic factor; Serum Ca; beta(2)-microglobulin; STAGING SYSTEM; PRESENTING FEATURES; IGD MYELOMA; FAILURE; SURVIVAL; EXPERIENCE; DIALYSIS;
D O I
10.1159/000319644
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The presence of renal failure in patients with multiple myeloma (MM) has been considered an ominous prognostic factor associated with a significantly decreased life expectancy. The prognostic factors have seldom been analyzed to predict discontinuation of hemodialysis (HD) therapy in MM patients with renal failure after HD initiation. It is clinically very important to predict whether HD can be discontinued after introducing HD in such patients. Methods: All medical and HD records were reviewed in MM patients who underwent HD in the National Center for Global Health and Medicine Hospital between January 1995 and May 2009. Thirty-two patients with MM had undergone HD. The clinical features and the factors that might be associated with recovery of renal function leading to discontinuation of HD in MM patients with severe renal failure were examined. Results: The factors associated with recovery of renal function and discontinuation of HD were: low International Staging System (ISS) score (p = 0.0034); high response to chemotherapy (p = 0.036); low serum Ca (p = 0.006); low Cr (p = 0.019), and low serum beta(2)-microglobulin (s beta M-2) (p = 0.002). On multivariate analysis, low serum Ca and s beta M-2 were significantly associated with HD discontinuation. Moreover, discontinuing HD was the significant factor associated with improved overall survival in MM patients who required HD at least once. Conclusion: s beta M-2 and Ca were the laboratory parameters that were significant, independent prognostic factors for predicting the probability of recovery from severe renal failure and discontinuation of HD in MM patients who needed HD at least once. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:C28 / C32
页数:5
相关论文
共 27 条
[1]  
ALEXANIAN R, 1990, Archives of Internal Medicine, V150, P1693, DOI 10.1001/archinte.150.8.1693
[2]   RENAL INVOLVEMENT IN IGD MYELOMA [J].
BERGESIO, F ;
SALVADORI, M ;
LOMBARDI, M ;
MICHELASSI, S ;
SALERNO, A ;
MONZANI, G ;
FLORIAN, A ;
IMREH, F ;
GUIDI, S .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1988, 22 (04) :309-312
[3]   Renal failure in multiple myeloma -: Presenting features and predictors of outcome in 94 patients from a single institution [J].
Bladé, J ;
Fernández-Llama, P ;
Bosch, F ;
Montoliu, J ;
Lens, XM ;
Montoto, S ;
Cases, A ;
Darnell, A ;
Rozman, C ;
Montserrat, E .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (17) :1889-1893
[4]   ACUTE RENAL-FAILURE IN MULTIPLE-MYELOMA [J].
DEFRONZO, RA ;
HUMPHREY, RL ;
WRIGHT, JR ;
COOKE, CR .
MEDICINE, 1975, 54 (03) :209-223
[5]   International uniform response criteria for multiple myeloma [J].
Durie, B. G. M. ;
Harousseau, J-L ;
Miguel, J. S. ;
Blade, J. ;
Barlogie, B. ;
Anderson, K. ;
Gertz, M. ;
Dimopoulos, M. ;
Westin, J. ;
Sonneveld, P. ;
Ludwig, H. ;
Gahrton, G. ;
Beksac, M. ;
Crowley, J. ;
Belch, A. ;
Boccadaro, M. ;
Turesson, I. ;
Joshua, D. ;
Vesole, D. ;
Kyle, R. ;
Alexanian, R. ;
Tricot, G. ;
Attal, M. ;
Merlini, G. ;
Powles, R. ;
Richardson, P. ;
Shimizu, K. ;
Tosi, P. ;
Morgan, G. ;
Rajkumar, S. V. .
LEUKEMIA, 2006, 20 (09) :1467-1473
[6]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
[7]  
2-U
[8]  
FIBBE WE, 1984, SCAND J HAEMATOL, V33, P471
[9]   Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].
Fonseca, R ;
Blood, E ;
Rue, M ;
Harrington, D ;
Oken, MM ;
Kyle, RA ;
Dewald, GW ;
Van Ness, B ;
Van Wier, SA ;
Henderson, KJ ;
Bailey, RJ ;
Greipp, PR .
BLOOD, 2003, 101 (11) :4569-4575
[10]   Multiple myeloma and renal failure [J].
Goldschmidt, H ;
Lannert, H ;
Bommer, J ;
Ho, AD .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (03) :301-304